Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Biokin Pharmaceutical
- Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary Endpoint
- Announcement on Resignation of the Secretary of Board of Directors and Assumption of the Secretary's Duties by Directors and Senior Management Members
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Earnings Preannouncement for 2025
- Notice on Convening the 1st Extraordinary General Meeting in 2026
Later from Sichuan Biokin Pharmaceutical
- Announcement on Progress in Repurchasing Shares
- Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for BL-M11D1 (CD33-ADC) Injection for the Treatment of Relapsed or Refractory Myelodysplastic Syndromes
- Announcement on Implementation Results of Share Repurchase
- Announcement on Circulation of Restricted Shares Issued to Specific Objects
- Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC002 in the Treatment of Advanced Solid Tumors
Follow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Biokin Pharmaceutical